Lantern Pharma Inc. (NASDAQ: LTRN) announced the expansion of its predictBBB platform into a Large Quantitative Model (LQM), delivering a real-time, web-based molecular intelligence engine that enables researchers to generate comprehensive developability profiles for small molecules from a single SMILES input. The enhanced platform leverages Lantern's RADR AI technology to provide rapid, high-dimensional analysis across physicochemical properties, drug-likeness, structural architecture and topological mapping, with benchmark-validated performance and accessibility designed to streamline drug discovery workflows and broaden access to advanced computational tools.
This expansion represents a significant step in Lantern's ongoing efforts to apply artificial intelligence and machine learning to oncology drug development. The predictBBB platform, originally focused on blood-brain barrier permeability prediction, now incorporates a broader range of molecular analysis capabilities. By converting the platform into an LQM, Lantern aims to provide researchers with a more comprehensive tool for evaluating drug candidates early in the discovery process, potentially reducing the time and cost associated with traditional methods.
The integration with Lantern's RADR platform allows for the processing of vast datasets to generate actionable insights. The company noted that the platform's benchmark-validated performance ensures reliability, while its web-based accessibility makes it available to a wide range of users without the need for specialized computational infrastructure. This democratization of advanced drug discovery tools could accelerate the identification of promising compounds across various therapeutic areas.
Lantern Pharma is a clinical-stage precision oncology company leveraging AI, machine learning, and its proprietary RADR platform to transform the development of cancer therapies. The company's clinical pipeline includes LP-184 (acylfulvene), LP-284 (a TC-NER targeting compound in hematologic and solid tumors), and LP-300 (cisplatin/ethacraplatin analog), which is being evaluated in the HARMONIC Phase 2 trial in never-smoker patients with relapsed advanced lung adenocarcinoma following TKI treatment. LP-184 is also being developed for pediatric CNS cancers through Starlight Therapeutics, Lantern's wholly owned CNS-focused subsidiary.
Additionally, Lantern's withZeta.ai platform, a multi-agentic AI co-scientist platform, is now commercially available as a subscription-based research platform for the global biomedical and drug development community, representing a new revenue stream for the company. Lantern operates an AI Center of Excellence in Bengaluru, India and is headquartered in Dallas, Texas.
For more information, visit the company's newsroom at https://ibn.fm/LTRN.
